Clinical Research Directory
Browse clinical research sites, groups, and studies.
Use of Hydrogen Sulphide Donor (N-acetyl Cysteine) in Cases With Acute Ischemic Stroke
Sponsor: Helwan University
Summary
1. Clarify novel systemic and local inflammatory mechanisms underlying the cross talk between brain and heart ischemic states, 2. Investigate the new aspects of NAC beyond traditional therapy, in cerebral and myocardial ischemic conditions, both in animal models and clinical cases.
Official title: Assessment of Therapeutic Role of H2S Donor in Acute Myocardial Infarction and Acute Cerebral Ischemia: Comparison in Animal Models and Clinical Cases.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
121
Start Date
2021-06-01
Completion Date
2024-03-01
Last Updated
2026-08-06
Healthy Volunteers
No
Conditions
Interventions
N Acetyl cysteine 600mg
* NAC was administered in a dose of 600 mg, every 8 hours, for 3 consecutive days, either through direct oral route, or indirectly through Ryle tube (in Ryle-feeding patients). * NAC was started shortly after hospital admission, following baseline assessment of patient. * NAC sachet form was used, so it was administrated as liquid oral solution, which was prepared from pure NAC powder, dissolved in water. * This recommended dose is within the approved therapeutic range (World Health Organization, 2021).
Normal (0.9%) saline
50 ml normal saline was administered either through direct oral route or through nasogastric tube in Ryle feeding patients.
Locations (1)
Stroke Unit, Neurology Department, Kasr Al Ainy, Cairo University Hospital
Cairo, Egypt